| Page 45 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.

Author(s): 
Peipert JD, Kulasekararaj AG, Gaya A, Langemeijer SMC, Yount S, Gonzalez-Fernandez FA, Ojeda Gutierrez E, Martens C, Sparling A, Webster KA, Cella D, Tomazos I, Ogawa M, Piatek CI, Wells R, Sicre de Fontbrune F, Röth A, Mitchell L, Hill A, Kaiser K
Primary Author: 
Peipert JD
Journal Title: 
PloS One
Original Publication Date: 
Sep 2020

Background: Eculizumab has transformed management of

Bone Marrow Disease(s): 

Talati Highlights “Game-Changing” Potential of Venetoclax/HMA Combos for Elderly AML

Chetasi Talati, MD, discusses early results from a multicenter chart review examining treatment patterns and outcomes of patients with newly diagnosed AML who received venetoclax/HMA combinations in the real-world setting and the next phase of the ongoing research initiative.

Chetasi Talati, MD
Chetasi Talati, MD

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Background
Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance on COVID-19 aimed to collect data from adult patients with haematological malignancies who required hospitalisation for COVID-19.
Methods

Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience

Author(s): 
Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM
Primary Author: 
Bewersdorf JP
Journal Title: 
Leukemia & Lymphoma
Original Publication Date: 
Sep 2020

Mutations in the tumor suppressor gene TP53 are detected in 5-10% of patients with

Bone Marrow Disease(s): 

High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity

Author(s): 
Caocci G, Vignetti M, Patriarca A, Breccia M, Platzbecker U, Palumbo GA, Stauder R, Cottone F, Petranovic D, Voso MT, Tafuri A, Invernizzi R, Caers J, Luppi M, La Nasa G, Niscola P, Efficace F
Primary Author: 
Caocci G
Journal Title: 
International Journal of Hematology
Original Publication Date: 
Aug 2020

We examined the association between serum

Bone Marrow Disease(s): 

Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab

Author(s): 
Macrae FL, Peacock-Young B, Bowman P, Baker SR, Quested S, Linton E, Hillmen P, Griffin M, Munir T, Payne D, McKinley C, Clarke D, Newton DJ, Hill A, Ariëns RAS
Primary Author: 
Macrae FL
Journal Title: 
American Journal of Hematology
Original Publication Date: 
Aug 2020

Bone Marrow Disease(s):